Minimally Invasive Hyperthermic Intraperitoneal Perfusion for Gastric Cancer
Patients diagnosed with stage IV gastric adenocarcinoma have traditionally been offered definitive chemotherapy or best supportive care. However, patients with metastases restricted to the peritoneal cavity, either with carcinomatosis or positive peritoneal cytology, may represent a population with further therapeutic options. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to be a safe operation for patients with carcinomatosis and positive peritoneal cytology from metastatic gastric adenocarcinoma and may lead to gastrectomy for select patients. Direct application of cytotoxic therapy to the peritoneum via HIPEC has been traditionally performed via laparotomy and has led to high morbidity. This innovative minimally invasive approach for select patients with metastatic gastric adenocarcinoma presents an opportunity for further treatment options with much lower morbidity.
KeywordsHyperthermic intraperitoneal chemotherapy HIPEC Gastric cancer Laparoscopic HIPEC
- 3.National Comprehensive Cancer Network Guidelines Version 1.2017. Gastric Cancer. Available at www.nccn.org. Accessed 1 May 2017.
- 4.Amin MB, et al., editors. American joint commission on cancer, staging manual, eighth edition. Stomach Cancer, p. 203–220.Google Scholar
- 15.Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–52.CrossRefGoogle Scholar
- 16.Badgwell B, Blum M, Das P, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018;32(1):512.Google Scholar